Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 3Waldenstrom Macroglobulinemia 1Stomatitis 1Lung Neoplasms 1Leukemia 1Head and Neck Neoplasms 1Glioblastoma 1Epstein-Barr Virus Infections 1Cytomegalovirus Infections 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

Valganciclovir 3Rituximab 3Cisplatin 3Vincristine 2Radiotherapy, Intensity-Modulated 2Prednisone 2Matrix-M 2Gemcitabine 2Etoposide 2Doxorubicin 2Cyclophosphamide 2pomalidomide 1dehydroftorafur 1brincidofovir 1Watchful Waiting 1Valacyclovir 1Tomography, X-Ray Computed 1Tenofovir 1Tegafur 1Taxes 1Platinum 1Phantoms, Imaging 1Paclitaxel 1Nivolumab 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Mitomycin 1Magnetic Resonance Spectroscopy 1Lenalidomide 1Interferons 1Fluorouracil 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epstein-Barr Virus Infections × Valacyclovir × 1 year × Clear all
NCT07294547 2025-12-19

Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study

National Taiwan University Hospital

Phase NA Recruiting
80 enrolled

Cytomegalovirus Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡